The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Minireview: Challenges and Opportunities in Development of PPAR Agonists
Open accessAbstract
The clinical impact of the fibrate and thiazolidinedione drugs on dyslipidemia and diabetes is driven mainly through activation of two transcription factors, peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ. However, substantial differences exist in the therapeutic and side-effect profiles of specific drugs. This has been attributed primarily to the complexity of drug-target complexes that involve many coregulatory proteins in the context of specific target gene promoters. Recent data have revealed that some PPAR ligands interact with other non-PPAR targets. Here we review concepts used to develop new agents that preferentially modulate transcriptional complex assembly, target more than one PPAR receptor simultaneously, or act as partial agonists. We highlight newly described on-target mechanisms of PPAR regulation including phosphorylation and nongenomic regulation. We briefly describe the recently discovered non-PPAR protein targets of thiazolidinediones, mitoNEET, and mTOT. Finally, we summarize the contributions of on- and off-target actions to select therapeutic and side effects of PPAR ligands including insulin sensitivity, cardiovascular actions, inflammation, and carcinogenicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“A large meta-analysis of clinical studies suggested that pioglitazone reduced the risk of myocardial infarction (MI) and stroke (18), whereas several reports suggested rosiglitazone has no effect on CV events (19) or may increase the risk of CV events (20).”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 1×
“Insulin-sensitizing and metabolic effects: identification of non-PPAR- targets of TZDs The divergent rank order potency for PPAR- activity of TZDs vs their antiinflammatory and antiproliferative effects has long suggested additional pharmacological activity that may contribute to their activity (65, 66).”
BackgroundChawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 2×
“Similarly, interferon- induction of inducible nitric oxide synthase and cyclooxygenase-2 is unaffected by PPAR- deficiency (96).”
BackgroundA Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila , and Humans
Bricker, D. K., Taylor, E. B., Schell, J. C., Orsak, T., Boutron, A., Chen, Y.-C., Cox, J. E., Cardon, C. M., Van Vranken, J. G., Dephoure, N., et al. (2012) · Science · doi:10.1126/science.1218099 · Cited by 843
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371 · cited 1×
“antidiabetic agents (116), the broader role of PPARs in”
BackgroundYue, T.-L., Chen, J., Bao, W., Narayanan, P. K., Bril, A., Jiang, W., Lysko, P. G., Gu, J.-L., Boyce, R., Zimmerman, D. M., et al. (2001) · Circulation · doi:10.1161/hc4601.099403 · Cited by 295
Gilde, A. J., & Van Bilsen, M. (2003) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.2003.01161.x · Cited by 178
Khandoudi, N., Delerive, P., Berrebi-Bertrand, I., Buckingham, R. E., Staels, B., & Bril, A. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1507 · Cited by 174
Colca, J. R., McDonald, W. G., Cavey, G. S., Cole, S. L., Holewa, D. D., Brightwell-Conrad, A. S., Wolfe, C. L., Wheeler, J. S., Coulter, K. R., Kilkuskie, P. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061551 · Cited by 171 · cited 2×
“Almost coincidentally, another group identified Mpc-2 (mTOT) to be a second direct mitochondrial target of pioglitazone, by photoaffinity and mass spectrometry-based proteomics approaches (Figure 3) (31).”
BackgroundSidell, R. J., Cole, M. A., Draper, N. J., Desrois, M., Buckingham, R. E., & Clarke, K. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1110 · Cited by 165 · cited 1×
“In obese Zucker fatty rats, treatment with rosiglitazone for 14 days normalized glucose uptake and protected the heart from ischemic injury (75).”
BackgroundPPARγ as a therapeutic target for tumor angiogenesis and metastasis
Panigraphy, D., Huang, S., Kieran, M. W., & Kaipainen, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.2014 · Cited by 137
Cited by
Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
Thiazolidinediones as antidiabetic agents: A critical review
Nanjan, M. J., Mohammed, M., Prashantha Kumar, B. R., & Chandrasekar, M. J. N. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.02.009 · Cited by 316
Moreno-Lanceta, A., Medrano-Bosch, M., Simón-Codina, B., Barber-González, M., Jiménez, W., & Melgar-Lesmes, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051452 · Cited by 19
“However, the use of full agonists in biological systems is greatly limited due to side effects [27–29].”
Metadata
- Authors
- Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-11-01
- Volume
- 28
- Issue
- 11
- Pages
- 1756-1768
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2059497015
- Cited by
- 168
- References
- 15
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.